+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Head And Neck Cancer - Pipeline Review, H1 2020

  • ID: 5024740
  • Drug Pipelines
  • April 2020
  • Region: Global
  • 2943 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • 2A Pharma AB
  • BioAtla LLC
  • Forbius
  • Jounce Therapeutics Inc
  • Noxopharm Ltd
  • Shionogi & Co Ltd
  • MORE
Head And Neck Cancer - Pipeline Review, H1 2020

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Head And Neck Cancer - Pipeline Review, H1 2020, provides an overview of the Head And Neck Cancer (Oncology) pipeline landscape.

Head and Neck Cancer is a cancer that arises in the head or neck region (in the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx). The common symptoms of cancer of the head and neck include persistent pain in the throat, pain or difficulty with swallowing, persistent hoarseness or a change in voice, pain in the ear and bleeding in the mouth or throat. The disease may be controlled by chemotherapy and radiation therapy.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Head And Neck Cancer - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Head And Neck Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Head And Neck Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Head And Neck Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 22, 185, 179, 1, 8, 113, 24 and 6 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, Preclinical, Discovery and Unknown stages comprises 10, 11, 1, 21, 4 and 1 molecules, respectively.

Head And Neck Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Head And Neck Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Head And Neck Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Head And Neck Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Head And Neck Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Head And Neck Cancer (Oncology)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Head And Neck Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Head And Neck Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • 2A Pharma AB
  • BioAtla LLC
  • Forbius
  • Jounce Therapeutics Inc
  • Noxopharm Ltd
  • Shionogi & Co Ltd
  • MORE
  • Introduction
  • Head And Neck Cancer - Overview
  • Head And Neck Cancer - Therapeutics Development
  • Head And Neck Cancer - Therapeutics Assessment
  • Head And Neck Cancer - Companies Involved in Therapeutics Development
  • Head And Neck Cancer - Drug Profiles
  • Head And Neck Cancer - Dormant Projects
  • Head And Neck Cancer - Discontinued Products
  • Head And Neck Cancer - Product Development Milestones
  • Appendix
List of Tables
  • Number of Products under Development for Head And Neck Cancer, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..3), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..4), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..5), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..6), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..7), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..8), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..9), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..10), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..11), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..12), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..13), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..14), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..15), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..16), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..17), H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020 (Contd..2), H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020
  • Products under Development by Universities/Institutes, H1 2020 (Contd..2), H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..2), H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..3), H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..4), H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..5), H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..6), H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..7), H1 2020
List of Figures
  • Number of Products under Development for Head And Neck Cancer, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Top 10 Routes of Administration, H1 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2020
  • Number of Products by Top 10 Molecule Types, H1 2020
  • Number of Products by Stage and Top 10 Molecule Types, H1 2020
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • 2A Pharma AB
  • 4D Pharma Plc
  • 4SC AG
  • A2 Biotherapeutics Inc
  • Aadi Bioscience Inc
  • AbbVie Inc
  • Abion Inc
  • ABL Bio Inc
  • Acepodia Biotech Inc
  • Adaptimmune Therapeutics Plc
  • ADC Therapeutics SA
  • Adlai Nortye Biopharma Co Ltd
  • Admedus Ltd
  • Aduro BioTech Inc
  • Advaxis Inc
  • Advenchen Laboratories LLC
  • Adze Biotechnology Inc
  • Affimed GmbH
  • Agenus Inc
  • Akeso Biopharma Inc
  • Alkermes Plc
  • Alligator Bioscience AB
  • Alphamab Oncology
  • ALX Oncology Inc
  • Ambrx Inc
  • amcure GmbH
  • Amgen Inc
  • AMI Onco Theranostics LLC
  • ANP Technologies Inc
  • AP Biosciences Inc
  • Apexigen Inc
  • Apollomics Inc
  • Arcus Biosciences Inc
  • Argenx SE
  • Ascenta Therapeutics Inc
  • Ascentage Pharma Group International
  • Asclepiumm Taiwan Co Ltd
  • AsclepiX Therapeutics Inc
  • Astellas Pharma Inc
  • Astex Pharmaceuticals Inc
  • AstraZeneca Plc
  • Atara Biotherapeutics Inc
  • Aura Biosciences Inc
  • Aurigene Discovery Technologies Ltd
  • Avalon GloboCare Corp
  • AVEO Oncology Inc
  • Aveta Biomics Inc
  • Avvinity Therapeutics Ltd
  • Bavarian Nordic A/S
  • Bayer AG
  • BeiGene Ltd
  • Bexion Pharmaceuticals LLC
  • Bio-Thera Solutions Ltd
  • BioAtla LLC
  • Biohaven Pharmaceutical Holding Company Ltd
  • BioLineRx Ltd
  • Biomics Biotechnologies Co Ltd
  • Biomimetix JV LLC
  • Biomunex Pharmaceuticals
  • BioNTech SE
  • Bioven Group
  • BJ Bioscience Inc
  • Boehringer Ingelheim International GmbH
  • Boryung ViGenCell Inc
  • Boston Biomedical Inc
  • BrightPath Biotherapeutics Co Ltd
  • Bristol-Myers Squibb Co
  • Brooklyn ImmunoTherapeutics LLC
  • Cancer Therapeutics Laboratories Inc
  • Canget BioTekpharma LLC
  • CanImGuide Therapeutics AB
  • Cantargia AB
  • CarboMimetics
  • CEL-SCI Corp
  • Celldex Therapeutics Inc
  • Cellectar Biosciences Inc
  • Cello Therapeutics Inc
  • Cellular Biomedicine Group Inc
  • Celprogen Inc
  • Centurion BioPharma Corp
  • Checkmate Pharmaceuticals Inc
  • Checkpoint Therapeutics Inc
  • Chi Cheung (Shanghai) Biomedical Co Ltd
  • China Immunotech Co Ltd
  • Corvus Pharmaceuticals Inc
  • Cotinga Pharmaceuticals Inc
  • CStone Pharmaceuticals Co Ltd
  • Cue Biopharma Inc
  • Cullinan Oncology LLC
  • Curevac AG
  • Cyclacel Pharmaceuticals Inc
  • Cyteir Therapeutics Inc
  • CytImmune Sciences Inc
  • Cytocom Inc
  • Cytodyn Inc
  • CytoMed Therapeutics Pte Ltd
  • CytomX Therapeutics Inc
  • Daiichi Sankyo Co Ltd
  • Debiopharm International SA
  • DelMar Pharmaceuticals Inc
  • DNJ Pharma Inc
  • Dragonboat Biopharmaceutical (Shanghai)Co Ltd
  • eFFECTOR Therapeutics Inc
  • Eisai Co Ltd
  • Eli Lilly and Co
  • Elicio Therapeutics
  • ENB Therapeutics LLC
  • EnGeneIC Ltd
  • Enzene Biosciences Ltd
  • EpicentRx Inc
  • Etubics Corp
  • Eutilex Co Ltd
  • Exelixis Inc
  • Exicure Inc
  • F. Hoffmann-La Roche Ltd
  • Fate Therapeutics Inc
  • Fochon Pharma Inc
  • Forbius
  • Fujifilm Holdings Corp
  • G&E Corp
  • Galectin Therapeutics Inc
  • GEEN Biotechnology Inc
  • Geneius Biotechnology Inc
  • Genelux Corp
  • Genentech Inc
  • Genmab AS
  • Genocea Biosciences Inc
  • GeoVax Labs Inc
  • Gilead Sciences Inc
  • GlaxoSmithKline Plc
  • GLG Pharma SA
  • Gliknik Inc
  • Glycomantra Inc
  • GlycoMira Therapeutics Inc
  • Glycotope GmbH
  • GT Biopharma Inc
  • Guangzhou Doublle Bioproduct Inc
  • Guangzhou Hanghua Bio Pharmaceutical Technology Co
  • Guangzhou Sinogen Pharmaceutical Co Ltd
  • Harbin Gloria Pharmaceuticals Co Ltd
  • Harbour BioMed
  • Hengenix Biotech Inc
  • Hercules Pharmaceuticals BV
  • Hookipa Pharma Inc
  • Horizon Therapeutics PLC
  • Hummingbird Bioscience Pte Ltd
  • HylaPharm
  • Idera Pharmaceuticals Inc
  • ImCheck Therapeutics SAS
  • Immatics Biotechnologies GmbH
  • ImmuneSensor Therapeutics Inc
  • Immunicum AB
  • ImmunityBio Inc
  • Immunocore Ltd
  • Immunomedics Inc
  • Immunomic Therapeutics Inc
  • Immutep Ltd
  • Immvira Co Ltd
  • IMV Inc
  • Incyte Corp
  • Infinity Pharmaceuticals Inc
  • Inhibrx Inc
  • Innate Pharma SA
  • Innovene
  • Innovent Biologics Inc
  • Inovio Pharmaceuticals Inc
  • Intensity Therapeutics Inc
  • InteRNA Technologies BV
  • Invectys SA
  • InxMed Shanghai Co Ltd
  • IO Biotech ApS
  • Iovance Biotherapeutics Inc
  • Ipsen SA
  • ISA Pharmaceuticals BV
  • iSTAT Therapeutics Inc
  • ISU ABXIS Co Ltd
  • Jacobio Pharmaceuticals Co Ltd
  • Jiangsu Hengrui Medicine Co Ltd
  • Jiangsu Kanion Pharmaceutical Co Ltd
  • Johnson & Johnson
  • Jounce Therapeutics Inc
  • Juno Therapeutics Inc
  • Kiromic BioPharma Inc
  • Kitov Pharma Ltd
  • Komipharm International Co Ltd
  • Konruns Pharmaceutical Co Ltd
  • Kuur Therapeutics Ltd
  • Kymab Ltd
  • Kyowa Kirin Co Ltd
  • L.E.A.F. Pharmaceuticals LLC
  • Laboratoires Pierre Fabre SA
  • LATITUDE Pharmaceuticals Inc
  • Leucid Bio Ltd
  • LIfT BioSciences Ltd
  • Lion TCR Pte Ltd
  • LipoSeuticals Inc
  • Luye Pharma Group Ltd
  • Luzitin SA
  • Lytix Biopharma AS
  • Mabion SA
  • MacroGenics Inc
  • MAIA Biotechnology Inc
  • Mateon Therapeutics Inc
  • Maverick Therapeutics Inc
  • MaxiVAX SA
  • MediciNova Inc
  • Medivir AB
  • Merck & Co Inc
  • Merck KGaA
  • Mereo Biopharma Group Plc
  • Mersana Therapeutics Inc
  • Mirati Therapeutics Inc
  • MiRecule Inc
  • MiReven Pty Ltd
  • Mitsubishi Tanabe Pharma Corp
  • Moderna Inc
  • Modra Pharmaceuticals BV
  • Molecular Partners AG
  • Molecular Templates Inc
  • Moleculin Biotech LLC
  • MolMed SpA
  • MultiVir Inc
  • Nanjing Iaso Biotherapeutics Co Ltd
  • NanoCarrier Co Ltd
  • NantBioScience Inc
  • NantKwest Inc
  • Natco Pharma Ltd
  • Nektar Therapeutics
  • Neonc Technologies Inc
  • NeoTX Therapeutics Ltd
  • Neumedicines Inc
  • NextCure Inc
  • NGM Biopharmaceuticals Inc
  • Northwest Biotherapeutics Inc
  • Novartis AG
  • Noxopharm Ltd
  • Ocellaris Pharma Inc
  • Ona Therapeutics SL
  • OncoImmune Inc
  • Oncologie Inc
  • Oncology Venture A/S
  • Oncolys BioPharma Inc
  • Onconova Therapeutics Inc
  • Oncorus Inc
  • OncoSec Medical Inc
  • Oncovir Inc
  • Ono Pharmaceutical Co Ltd
  • Onxeo SA
  • Otsuka Holdings Co Ltd
  • Oxford Vacmedix UK Ltd
  • PDS Biotechnology Corp
  • Pfizer Inc
  • Pharma Mar SA
  • Philogen SpA
  • Phio Pharmaceuticals Corp
  • Phosplatin Therapeutics LLC
  • PIQUR Therapeutics AG
  • Plexxikon Inc
  • Plus Therapeutics Inc
  • PNP Therapeutics Inc
  • Polaris Pharmaceuticals Inc
  • Potenza Therapeutics Inc
  • Precigen Inc
  • PRISM Pharma Co Ltd
  • Privo Technologies Inc
  • Protheragen Inc
  • PsiOxus Therapeutics Ltd
  • QBiotics Ltd
  • Qilu Pharmaceutical Co Ltd
  • Qilu Puget Sound Biotherapeutics Corp
  • Qrono Inc
  • R Pharm
  • Rakuten Medical Inc
  • RAPT Therapeutics Inc
  • RaQualia Pharma Inc
  • Refuge Biotechnologies Inc
  • Regeneron Pharmaceuticals Inc
  • Rimo Therapeutics Inc
  • Sanofi
  • Sareum Holdings Plc
  • Scancell Holdings Plc
  • Seattle Genetics Inc
  • SEEKYO Therapeutics
  • Selecta Biosciences Inc
  • Sensei Biotherapeutics Inc
  • Shanghai GeneChem Co Ltd
  • Shanghai Henlius Biotech Inc
  • Shanghai Jing Ze Biotechnology Co Ltd
  • Shanghai Junshi Bioscience Co Ltd
  • Shanghai Miracogen Inc
  • Shattuck Labs Inc
  • Shionogi & Co Ltd
  • Sichuan Kelun Pharmaceutical Co Ltd
  • Sierra Oncology Inc
  • Sillajen Biotherapeutics
  • Sino Biopharmaceutical Ltd
  • Sinocelltech Ltd
  • Sirnaomics Inc
  • Sirona Therapeutics Inc
  • SL Bigen Inc
  • SMET Pharmaceutical Inc
  • Soricimed Biopharma Inc
  • Sotio AS
  • Spring Bank Pharmaceuticals Inc
  • SQZ Biotechnologies Co
  • STAT3 Therapeutics Inc
  • Stcube Inc
  • Stella Pharmaceuticals Pvt Ltd
  • StemMed Ltd
  • Sumitomo Dainippon Pharma Co Ltd
  • SuviCa Inc
  • Suzhou Max Bio-tech Co Ltd
  • Suzhou Zelgen Biopharmaceutical Co Ltd
  • Sveikatal Inc
  • Synermore Biologics Co Ltd
  • Tactical Therapeutics Inc
  • Takis Srl
  • Tallikut Pharmaceuticals Inc
  • TCRCure Biotech Co Ltd
  • Telix Pharmaceuticals Ltd
  • Tempest Therapeutics Inc
  • Tessa Therapeutics Pte Ltd
  • Theralase Technologies Inc
  • Theravectys SA
  • Tolero Pharmaceuticals Inc
  • Torque Therapeutics Inc
  • TOT Biopharm Co Ltd
  • Transgene SA
  • Trovagene Inc
  • Turning Point Therapeutics Inc
  • Turnstone Biologics Inc
  • Tvardi Therapeutics Inc
  • Tyme Technologies Inc
  • UbiVac LLC
  • Vaccibody AS
  • Vaccinex Inc
  • VasGene Therapeutics Inc
  • Vault Pharma Inc
  • VCN Biosciences SL
  • Veana Therapeutics LLC
  • Vectorite Biomedical Inc
  • Venus Remedies Ltd
  • Verastem Inc
  • Viracta Therapeutics Inc
  • Viralytics Pty Ltd
  • Virion Therapeutics LLC
  • Voronoi
  • Vyriad Inc
  • Wayshine Biopharma Inc
  • Wuhan Binhui Biotechnology Co Ltd
  • Xbrane Biopharma AB
  • Xencor Inc
  • Xiangxue Life Sciences
  • XuanZhu Pharma Co Ltd
  • Xynomic Pharmaceuticals Holdings Inc
  • Zhejiang Yangshengtang Biotech Co Ltd
  • Zhengda Tianqing Kangfang Shanghai Biomedical Technology Co Ltd
  • Zymeworks Inc
Note: Product cover images may vary from those shown
Adroll
adroll